FEB 1 2003 PADENTE Attorney Docket No. 1909.03

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: WETTSTEIN et al. Serial No.: 10/099,924)	Group Art Unit: 1632	44		
Filed: March 14, 2002 For: SURVIVIN-INTERACTING PROTEINS AND USE THEREOF)	Examiner: Unassigned	2/23/0)		
		REC	CFIVED		

February 10, 2003

FEB 1 9 2003

Commissioner for Patents Washington, DC 20231

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

Attached is a list of documents on form PTO-1449 together with copies of each identified document. It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 CFR 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicants in no way make any admission as to prior art status of the listed documents, but are instead submitting the listed documents for the sake of full disclosure.

It is not believed that any extension of time, or any fee is required in connection with this communication. However, if an extension of time (and extension fee) or fees are required, such an extension of time is hereby petitioned for and the Commissioner is authorized to charge any fees or credit any overpayment to Deposit Account No. 50-1627.

Respectfully submitted,

Jay Z. Zhang

Registration No. 44,033

Intellectual Property Department Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, UT 84108
Telephone: 801-584-3600

Fax:

801-584-3640

In re Application of: WETTSTEIN et al.

Serial No.: 10/099,924 Filed: March 14, 2002

Page 2

CERTIFICATE OF EXPRESS MAIL

"Express Mail" mailing label number EV 295123436 US Date of Deposit: February 10, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Commissioner for Patents, Washington, DC 20231.

Michael Moreno

2-10-53

Date

\Intellectual Property\Patent Prosecution\1900-1999\1909\1909.03\1909.03 2003-02-10 IDS COVER MM.doc

FEB 1 1 2003 ENT & TRADEN

ubstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known RECEIVED **Application Number** 10/099,924 Filing Date March 14, 2002 First Named Inventor **Daniel Albert WETTSTEIN** FEB 1 9 2003 **Group Art Unit** 1632 **Examiner Name** Unassigned

(use as many sheets as necessary) Sheet 2

<u>. </u>	Attorney Docket Number	1909.03		

Sheet		1	of		2 Attorney Docke	t Number	1909.03	Trough	
									0/2900
					U.S. PATENT DOCU	MENTS			V/2300
Examiner Initials'	Cite No. ¹	U.S. Pate Number	nt Documents Kind Code (if known)	e ² Na	me of Patentee or Applicant of Cited Documents	Date of Publica of Cited Docur MM-DD-YYY	nent	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear	

	1	OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, volume-issue number(s), page(s), publisher, city and/or country where published.	T
	B1	NAORA, Honami, et al., "Differential Expression Patterns of β-Actin mRNA In Cells Undergoing Apoptosis", <i>Biochemical and Biophysical Research Communications</i> , June 15, 1995; 211(2):491-196	
	B2	JAFFREY, Samie R., et al., "PIN: An Associated Protein Inhibitor of Neuronal Nitric Oxide Synthase", <i>Science</i> , November 1, 1996; 274:774-777	
	В3	CAHILL, Daniel P., "Mutations of mitotic checkpoint genes in human cancers", <i>Nature</i> , March 19, 1998; 392:300-303	
	B4	AMBROSINI, Grazia, et al., "Induction of Apoptosis and Inhibition of Cell Proliferation by survivin Gene Targeting", The Journal of Biological Chemistry, May 1, 1998; 273(18):11177-11182	
	B5	LI, Gloria C., et al., "Ku70: A Candidate Tumor Suppressor Gene for Murine T Cell Lymphoma", Molecular Cell, July 1998; 2:1-8	
	В6	LI, Fengzhi, et al., "Control of apoptosis and mitotic spindle checkpoint by survivin", Nature, December 10, 1998; 396:580-584	
	В7	MASHIMA, Tetsuo, et al., "Caspase-mediated cleavage of cytoskeletal actin plays a positive roll in the process of morphological apoptosis", <i>Oncogene</i> , 1999; 18:2423-2430	
	B8	TAKEDA, Yoshihiko, et al., "Human RNA Helicase A Is a Lupus Autoantigen That Is Cleaved During Apoptosis", <i>The Journal of Immunology</i> , 1999; 163:6269-6274	
	В9	TRAN, Jennifer, et al., "Marked Induction of the IAP Family Antiapoptotic Proteins Survivin and XIAP by VEGF in Vascular Endothelial Cells", <i>Biochemical and Biophysical Research Communications</i> , 1999; 264:781-788	
	B10	BUOLAMWINI, John K., "Novel anticancer drug discovery", Current Opinion in Chemical Biology, 1999; 3:500-509	
	B11	METCALFE, Su, et al., "Wild-type p53 protein shows calcium-dependent binding to F-actin", Oncogene, 1999; 18:2351-2355	
D.D.	B12	GOEDECKE, Wolfgang, et al., "Mre11 and Ku70 interact in somatic cells, but are differentially expressed in early meiosis", <i>Nature Genetics</i> , October 1999; 23:194-198	
	B13	ALTIERI, Dario C., et al., "Survivin Apoptosis: An Interloper Between Cell Death and Cell Proliferation in Cancer", Laboratory Investigation, November 1999; 79(11):1327-1333	
	B14	SUAREZ-HUERTA, Nathalie, et al., "Actin Depolymerization and Polymerization Are Required During Apoptosis in Endothelial Cells", <i>Journal of Cellular Physiology</i> , 2000; 184:239-245	
	B15	ROSSITER, J.P., et al., "Caspase-cleaved actin (fractin) immunolabelling of Hirano bodies", Neuropathology and Applied Neurobiology, 2000; 26:342-346	
	B16	SARELA, A.I., "Expression of the antiapoptosis gene, <i>Survivin</i> , predicts death from recurrent colorectal carcinoma", <i>Gut</i> , 2000; 46:645-650	

	B17	SUZUKI, Atsushi, et al., "Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 ^{INK4a} and Cdk2/Cyclin E complex activation", Oncogene, 2000; 19:3225-3234				
	B18	SUZUKI, Atsushi, et al., "Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death", Oncogene, 2000; 19:1346-1353				
	B19	O'CONNOR, Daniel S., "Control of Apoptosis during Angiogenesis by Survivin Expression in Endothelial Cells", <i>American Journal of Pathology</i> , February 2000; 156(2):393-398				
	B20	BROWN, Kevin D., et al., "Ionizing Radiation Exposure Results in Up-regulation of Ku70 via a p53/Ataxia-Telangiectasia-mutated Protein-dependent Mechanism", <i>The Journal of Biological Chemistry</i> , March 3, 2000; 275(9):6651-6656				
	B21	CHEN, Jun, et al., "Down-regulation of Survivin by Antisense Oligonucleotides Increases Apoptosis, Inhibits Cytokinesis and Anchorage-Independent Growth", Neoplasia, May-June 2000; 2(3):235-241				
	B22	YANG, Chin-Rang, et al., "Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death", <i>PNAS</i> , May 23, 2000; 97(11):5907-5912				
	B23	OLIE, Robert A., et al., "A Novel Antisense Oligonucleotide Targeting Survivin Expression Induces Apoptosis and Sensitizes Lung Cancer Cells to Chemotherapy", Cancer Research, June 1, 2000; 60:2805-2809				
	B24	SHIN, Sejeong, et al., "An Anti-apoptotic Protein Human Survivin Is a Direct Inhibitor of Caspase-3 and -7", <i>Biochemistry</i> , 2001; 40:1117-1123				
	B25	GROSSMAN, Douglas, et al., "Inhibition of melanoma tumor growth <i>in vivo</i> by survivin targeting", <i>PNAS</i> , January 16, 2001; 98(2):635-640				
	1					
xaminer Signature	1;		Date Considered			

\\Mgint2\\Shared Folder-All\\Intellectual Property\Patent Prosecution\1900-1999\1909\00003\1909.03\1909.03\2003-02-10 IDS MM.doc

RECEIVED

FEB 1 9 2003

TECH CENTER 1600/2900